Show simple item record

dc.contributor.authorWard, H
dc.contributor.authorCooke, GS
dc.contributor.authorAtchison, C
dc.contributor.authorWhitaker, M
dc.contributor.authorElliott, J
dc.contributor.authorMoshe, M
dc.contributor.authorBrown, JC
dc.contributor.authorFlower, B
dc.contributor.authorDaunt, A
dc.contributor.authorAinslie, K
dc.contributor.authorAshby, D
dc.contributor.authorDonnelly, CA
dc.contributor.authorRiley, S
dc.contributor.authorDarzi, A
dc.contributor.authorBarclay, W
dc.contributor.authorElliott, P
dc.date.accessioned2021-07-29T10:18:05Z
dc.date.available2021-07-29T10:18:05Z
dc.date.issued2021-05-02
dc.identifier.citationThe Lancet regional health. Europe, 2021, 4 pp. 100098 - ?
dc.identifier.issn2666-7762
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4711
dc.identifier.eissn2666-7762
dc.identifier.eissn2666-7762en_US
dc.identifier.doi10.1016/j.lanepe.2021.100098
dc.identifier.doi10.1016/j.lanepe.2021.100098en_US
dc.description.abstractBackground The time-concentrated nature of the first wave of the COVID-19 epidemic in England in March and April 2020 provides a natural experiment to measure changes in antibody positivity at the population level before onset of the second wave and initiation of the vaccination programme.Methods Three cross-sectional national surveys with non-overlapping random samples of the population in England undertaken between late June and September 2020 (REACT-2 study). 365,104 adults completed questionnaires and self-administered lateral flow immunoassay (LFIA) tests for IgG against SARS-CoV-2.Findings Overall, 17,576 people had detectable antibodies, a prevalence of 4.9% (95% confidence intervals 4.9, 5.0) when adjusted for test characteristics and weighted to the adult population of England. The prevalence declined from 6.0% (5.8, 6.1), to 4.8% (4.7, 5.0) and 4.4% (4.3, 4.5), over the three rounds of the study a difference of -26.5% (-29.0, -23.8). The highest prevalence and smallest overall decline in positivity was in the youngest age group (18-24 years) at -14.9% (-21.6, -8.1), and lowest prevalence and largest decline in the oldest group (>74 years) at -39.0% (-50.8, -27.2). The decline from June to September 2020 was largest in those who did not report a history of COVID-19 at -64.0% (-75.6, -52.3), compared to -22.3% (-27.0, -17.7) in those with SARS-CoV-2 infection confirmed on PCR.Interpretation A large proportion of the population remained susceptible to SARS-CoV-2 infection in England based on naturally acquired immunity from the first wave. Widespread vaccination is needed to confer immunity and control the epidemic at population level.Funding This work was funded by the Department of Health and Social Care in England.
dc.formatPrint-Electronic
dc.format.extent100098 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titlePrevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults.
dc.typeJournal Article
dcterms.dateAccepted2021-03-23
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.lanepe.2021.100098
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2021-05-02
rioxxterms.licenseref.startdate2021-05-02en_US
dc.relation.isPartOfThe Lancet regional health. Europe
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume4en_US
pubs.embargo.termsNot known
dc.contributor.icrauthorDarzi, Araen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/